BioSpace1d
OPKO and Entera Link Up to Advance First Oral GLP-1/Glucagon Drug Into Clinic
Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.
Pharmaceutical Technology on MSN1d
Opko and Entera focus on oral care for obesity and metabolic disorders
Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...
Opko Health, Entera Bio enter collaboration agreement for GLP-1/glucagon peptide
OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual ...
BioWorld1d
Opko Health, Entera Bio sign agreement for oral GLP-1/glucagon dual agonist peptide
Opko Health Inc. and Entera Bio Ltd. have entered into a collaboration and license agreement to advance an oral dual agonist GLP-1/glucagon peptide as a once-daily tablet into the clinic for patients ...